Niemann, C. U. Et Al. 2023. Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology , vol.24, no.12 , 1423-1433.

Niemann, C. U., Munir, T., Moreno, C., Owen, C., Follows, G. A., Benjamini, O., ... Janssens, A.(2023). Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology , vol.24, no.12, 1423-1433.

Niemann, Carsten Et Al. "Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial," The Lancet Oncology , vol.24, no.12, 1423-1433, 2023

Niemann, Carsten U. Et Al. "Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial." The Lancet Oncology , vol.24, no.12, pp.1423-1433, 2023

Niemann, C. U. Et Al. (2023) . "Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial." The Lancet Oncology , vol.24, no.12, pp.1423-1433.

@article{article, author={Carsten U Niemann Et Al. }, title={Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial}, journal={The Lancet Oncology}, year=2023, pages={1423-1433} }